Please provide your email address to receive an email when new articles are posted on . Adding tarlatamab to durvalumab for first-line maintenance therapy extended OS and PFS in extensive-stage small ...
A monthly 300 mg dose of ianalumab demonstrated greater reductions in disease activity vs. placebo at 48 weeks among patients with Sjögren’s disease, according to data from two trials published in the ...
A conversation with two clients recently reinforced an important lesson about charitable giving: the best way to donate is rarely the same for everyone.
Subcutaneous Weltruza, approved by the FDA in October, provides a new once-monthly treatment option for people with ...
Throughout my ophthalmology training, I have actively sought opportunities to expand my surgical skills beyond residency and ...
Adherence to a Mediterranean-style diet was associated with lower odds for acne in adults, according to a study published in the Journal of the European Academy of Dermatology and Venerology.Among 228 ...
Osteopathic manipulative treatment could be a safe and feasible option for infants with plagiocephaly — also known as “flat head syndrome” — according to study results presented at the AAP National ...
In this video from Retina Subspecialty Day at the American Academy of Ophthalmology meeting, Sharon Fekrat, MD, FACS, FASRS, highlights a debate on whether residual subretinal fluid can be tolerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results